An Anti-CD7 Antibody–Drug Conjugate Target Showing Potent Antitumor Activity for T-Lymphoblastic Leukemia (T-ALL)
Open Access
- 15 January 2024
- journal article
- research article
- Published by MDPI AG in Biomolecules
- Vol. 14 (1) , 106
Abstract
Acute T-lymphoblastic leukemia (T-ALL) is a type of leukemia that can occur in both pediatric and adult populations. Compared to acute B-cell lymphoblastic leukemia (B-ALL), patients with T-cell T-ALL have a poorer therapeutic efficacy. In this study, a novel anti-CD7 antibody–drug conjugate (ADC, J87-Dxd) was successfully generated and used for T-ALL treatment. Firstly, to obtain anti-CD7 mAbs, we expressed and purified the CD7 protein extracellular domain. Utilizing hybridoma technology, we obtained three anti-CD7 mAbs (J87, G73 and A15) with a high affinity for CD7. Both the results of immunofluorescence and Biacore assay indicated that J87 (KD = 1.54 × 10−10 M) had the highest affinity among the three anti-CD7 mAbs. In addition, an internalization assay showed the internalization level of J87 to be higher than that of the other two mAbs. Next, we successfully generated the anti-CD7 ADC (J87-Dxd) by conjugating DXd to J87 via a cleavable maleimide-GGFG peptide linker. J87-Dxd also possessed the ability to recognize and bind CD7. Using J87-Dxd to treat T-ALL cells (Jurkat and CCRF-CEM), we observed that J87-Dxd bound to CD7 was internalized into T-ALL cells. Moreover, J87-Dxd treatment significantly induced the apoptosis of Jurkat and CCRF-CEM cells. The IC50 (half-maximal inhibitory concentration) value of J87-Dxd against CCRF-CEM obtained by CCK-8 assay was 6.3 nM. Finally, to assess the antitumor efficacy of a J87-Dxd in vivo, we established T-ALL mouse models and treated mice with J87-Dxd or J87. The results showed that on day 24 after tumor inoculation, all mice treated with J87 or PBS died, whereas the survival rate of mice treated with J87-Dxd was 80%. H&E staining showed no significant organic changes in the heart, liver, spleen, lungs and kidneys of all mice. In summary, we demonstrated that the novel anti-CD7 ADC (J87-Dxd) had a potent and selective effect against CD7-expressing T-All cells both in vitro and in vivo, and could thus be expected to be further developed as a new drug for the treatment of T-ALL or other CD7-expression tumors.Keywords
Funding Information
- National Natural Science Foundation of China (82073404, ZYJC21003, TFJC2023010006, 2022CJE09013, 2023HXBH099)
- 1·3·5 project for disciplines of excellence, West China Hospital, Sichuan University (82073404, ZYJC21003, TFJC2023010006, 2022CJE09013, 2023HXBH099)
- Frontiers Medical Center, Tianfu Jincheng Laboratory Foundation (82073404, ZYJC21003, TFJC2023010006, 2022CJE09013, 2023HXBH099)
- Major scientific and technological achievements transformation project, Ningxia Hui Autonomous Region (82073404, ZYJC21003, TFJC2023010006, 2022CJE09013, 2023HXBH099)
- Post-Doctor Research Project, West China Hospital, Sichuan University (82073404, ZYJC21003, TFJC2023010006, 2022CJE09013, 2023HXBH099)
This publication has 30 references indexed in Scilit:
- Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic LeukemiaJAMA Oncology, 2017
- Novel CD7-specific nanobody-based immunotoxins potently enhanced apoptosis of CD7-positive malignant cellsOncotarget, 2016
- DIAGNOSIS AND SUBCLASSIFICATION OF ACUTE LYMPHOBLASTIC LEUKEMIAMediterranean Journal of Hematology and Infectious Diseases, 2014
- Long-term complications and side effects after allogeneic hematopoietic stem cell transplantation: an updateBlood Cancer Journal, 2011
- T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993)Blood, 2009
- Targeted therapy in T-cell malignancies: dysregulation of the cellular signaling pathwaysLeukemia, 2009
- Anti-peptide antibody screening: Selection of high affinity monoclonal reagents by a refined surface plasmon resonance techniqueJournal of Immunological Methods, 2009
- Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemiaLeukemia Research, 2004
- A recombinant CD7-specific single-chain immunotoxin is a potent inducer of apoptosis in acute leukemic T cells.2002
- Therapy with CD7 monoclonal antibody TH‐69 is highly effective for xenografted human T‐cell ALLBritish Journal of Haematology, 1996